FIELD: pharmaceuticals.
SUBSTANCE: invention refers to a compound which can be used in pharmaceutical industry, formula:
,
or its pharmaceutically acceptable salt.
EFFECT: disclosed is a novel compound effective as a STING modulator.
3 cl, 11 ex, 1 tbl, 4 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODY-STING AGONIST CONJUGATES AND USE THEREOF IN IMMUNOTHERAPY | 2020 |
|
RU2826228C2 |
| CYCLIC DI-NUCLEOTIDE COMPOUNDS FOR TREATMENT OF CANCER | 2018 |
|
RU2790175C2 |
| CYTOSKELETON-ACTIVE COMPOUNDS, COMPOSITIONS AND USE | 2006 |
|
RU2407745C2 |
| MACROCYCLIC COMPOUNDS AS STING AGONISTS AND METHODS USING THEM AND WAYS OF USE THEREOF | 2020 |
|
RU2825271C2 |
| REGULATORS-DERIVATIVES OF STEROIDS, METHODS OF THEIR OBTAINING AND THEIR USE | 2019 |
|
RU2797408C2 |
| BICYCLIC AGONISTS OF THE INTERFERON GENE STIMULATOR STING | 2020 |
|
RU2800072C1 |
| COMPOUND (6-{[(1S)-1(5-FLUORO-4-OXO-3-PHENYL-3,4-DIHYDROQUINAZOLIN-2-YL)PROPYL]AMINO}-9H-PURIN-9-YL)METHYL ACETATE AS INHIBITOR OF P110δ- DELTA ISOFORM OF PHOSPHOINOSITIDE-3-KINASE (PI3K), METHODS FOR ITS PRODUCTION (OPTIONS) AND APPLICATIONS | 2018 |
|
RU2675237C1 |
| ANTIVIRAL ALIPHATIC ESTER PRODRUGS OF TENOFOVIR | 2017 |
|
RU2759902C2 |
| AGONIST OF THE GLUCOCORTICOID RECEPTOR AND ITS IMMUNOCONJUGATES | 2017 |
|
RU2745748C2 |
| MACROHETEROCYCLIC NUCLEOSIDE DERIVATIVES AND ANALOGUES THEREOF, PRODUCTION AND USE | 2017 |
|
RU2731385C1 |
